The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Therapeutic Innovation and Regulatory Science

• Publication date

  2013-01-25

• Fields of study

  Medicine, Business, Economics

• Identifiers
  DOI 10.1177/2168479012471945PMID 30227521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A global analysis of technological change in health care: the case of heart attacks. The TECH Investigators.

  2018cited by this paper
• The Increasing Necessity for Market-Based Pharmaceutical Prices

  2012cited by this paper
• Index of Economic Freedom

  2012cited by this paper
• The Global Competitiveness Report 2010-2011: Highlights

  2011cited by this paper
• The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan.

  2011cited by this paper
• Access to orphan drugs despite poor quality of clinical evidence.

  2011cited by this paper
• On the Relevance of Freedom and Entitlement in Development: New Empirical Evidence (1975-2007)

  2011cited by this paper
• Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale

  2011cited by this paper
• US pharmaceutical innovation in an international context.

  2010cited by this paper
• The problem of orphan drugs

  2010cited by this paper
• Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007

  2010cited by this paper
• The importance of new companies for drug discovery: origins of a decade of new drugs

  2010cited by this paper
• Drug pricing and value in oncology.

  2010cited by this paper
• Prescription drug accessibility and affordability in the United States and abroad.

  2010cited by this paper
• Rare Diseases and Orphan Products: Accelerating Research and Development

  2010cited by this paper
• The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and public health

  2009cited by this paper
• concise encyclopedia of economics

  2008cited by this paper
• Are meticillin-resistant Staphylococcus aureus bloodstream infection targets fair to those with other types of healthcare-associated infection or cost-effective?

  2008cited by this paper
• Patient access to pharmaceuticals: an international comparison

  2007cited by this paper
• The demise of the blockbuster?

  2007cited by this paper
• The diffusion of medical technology, local conditions, and technology re-invention: a comparative case study on coronary stenting.

  2006cited by this paper
• Lucrative niches: how drugs for rare diseases became lifeline for companies.

  2005cited by this paper
• International variation in prescribing antihypertensive drugs: Its extent and possible explanations

  2005cited by this paper
• Drugs for exceptionally rare diseases: do they deserve special status for funding?

  2005cited by this paper
• Managing drugs for rare genetic diseases: trends and insights.

  2005cited by this paper
• Are market forces strong enough to deliver efficient health care systems? Confidence is waning.

  2004cited by this paper
• A new policy framework for health care markets.

  2004cited by this paper
• The relationship between market-based pricing and biopharmaceutical innovation.

  2004cited by this paper
• The relationship between market-based pricing and biopharmaceutical innovation.

  2004cited by this paper
• The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

  2003cited by this paper
• Orphan drug product regulation--United States.

  2002cited by this paper
• Applying economic principles to health care.

  2001cited by this paper
• The Health of Organizations

  2001cited by this paper
• Free for All? Lessons from the RAND Health Insurance Experiment

  2001cited by this paper
• Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues.

  2000cited by this paper
• 1997 Index of Economic Freedom

  1997cited by this paper
• ECONOMIC FREEDOM, PROSPERITY, AND EQUALITY: A SURVEY

  1997cited by this paper
• Has the erosion of the medical marketplace ended?

  1988cited by this paper
• Applied Multivariate Statistical Analysis

  1983cited by this paper
• The erosion of the medical marketplace.

  1981cited by this paper
• New Product Adoption and Diffusion

  1976cited by this paper

• Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework

  2014cites this paper